With no news catalysts, no options sentiment read, and deteriorating financials, there’s no strong edge to buy immediately.
A better “buy-now” case would require either a clear reversal (reclaiming/pushing above the 5.21 pivot) or a fresh Intellectia entry signal; neither is present.
Technical Analysis
Price (4.87) is below the pivot (5.211), keeping the near-term bias bearish.
Moving averages are bearish (SMA_200 > SMA_20 > SMA_5), indicating a sustained downtrend.
MACD histogram is negative (-0.0379) but contracting: downside momentum is easing, yet not reversed.
RSI(6) at 36.13 is weak (near oversold territory) and can support a short-term bounce, but it’s not a confirmed buy signal.
Key levels: Support S1 = 4.709 (near-term line in the sand), then S2 = 4.398; Resistance R1 = 5.713, R2 = 6.024.
Positive Catalysts
with RSI weak and MACD downside momentum contracting, which can allow a reflex bounce.
Neutral/Negative Catalysts
with price below the pivot.
Financial Performance
Latest reported quarter: 2025/Q3.
Revenue: 0 (no YoY growth; effectively pre/early commercial stage).
Net income: -5.41M, worsening YoY (-9.44%).
EPS: -0.25, down YoY (-19.35%).
Overall: losses are widening and there is no revenue ramp visible in the snapshot, which weakens the fundamental “buy-now” case.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
No analyst rating or price target change data provided, so no identifiable recent Wall Street upgrade/downgrade trend.
Pros (typical bull view framework): potential upside is primarily catalyst-driven (pipeline/clinical/strategic updates), not visible in this dataset.
Cons (current dataset): absent catalyst signals + worsening losses + bearish technicals make the near-term risk/reward unattractive for an immediate entry.
Wall Street analysts forecast ACTU stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ACTU is 22.5 USD with a low forecast of 20 USD and a high forecast of 25 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast ACTU stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ACTU is 22.5 USD with a low forecast of 20 USD and a high forecast of 25 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 4.320
Low
20
Averages
22.5
High
25
Current: 4.320
Low
20
Averages
22.5
High
25
B. Riley
NULL -> Buy
initiated
$20
AI Analysis
2025-08-26
Reason
B. Riley
Price Target
$20
AI Analysis
2025-08-26
initiated
NULL -> Buy
Reason
B. Riley initiated coverage of Actuate Therapeutics with a Buy rating and $20 price target. The firm views the company's lead asset elraglusib as a "transformative" advancement in pancreatic ductal adenocarcinoma treatment. In a Phase 2 study, elraglusib delivered an "unprecedented" survival benefit in the front-line setting with a 37% reduction in death risk that remained consistent in more aggressive disease characterized by the presence of liver metastasis, the analyst tells investors in a research note.
